Neo-Darbazine Spansule Capsule No.1 - Share Your Neo-Darbazine Spansule Capsule No.1 Experience with Community:
blog comments powered by DisqusNADA Number: 031-914 | |
| Proprietary Name |
Neo-Darbazine Spansule Capsule No.1 Neo-Darbazine Spansule Capsule No.3 |
|---|---|
| Sponsor |
Pfizer, Inc. |
| Sponsor Address |
235 East 42d St. New York, NY 10017 USA |
| Ingredients |
Isopropamide Iodide Prochlorperazine Dimaleate Neomycin Sulfate |
| Species |
Dog, no use class stated or implied |
| Routes of Administration |
Per Os |
| Dose Form |
Sustained release capsule |
| Drug Form |
Sustained release capsule |
| Dispensing Status |
RX |
|
Dosage Amount, Indications & Limitations |
520.1921 Prochlorperazine, isopropamide with neomycin sustained-release capsules. Specifications: Each capsule contains either Capsule No. 1 which contains 3.33 milligrams of prochlorperazine (as the dimaleate), 1.67 milligrams of isopropamide (as the iodide), and 25 milligrams of neomycin base (as the sulfate) or Capsule No. 3 which contains 10 milligrams of prochlorperazine (as the dimaleate), 5 milligrams of isopropamide (as the iodide), and 75 milligrams of neomycin base (as the sulfate). Conditions of use: Dogs Amount: 10 to 20 pounds body weight- 1 #1 capsule, orally twice daily to dogs. 20 to 30 pounds body weight- 2 #1 capsules, orally twice daily to dogs. Over 30 pounds body weight- 3 #1 capsules or 1 #3 capsules, orally twice daily to dogs. Over 60 pounds- 2 #3 capsules, orally twice daily to dogs. Indications: For treatment of dogs in which infectious bacterial gastroenteritis is associated with emotional stress. Limitations: Do not continue medication longer than 5 days. Overdosage or prolonged administration may produce nephrotoxicity as manifested by albuminuria, presence of granular casts and depressed urinary output. If it is desirable to administer a vasoconstrictor, norepinephrine is the drug of choice. Federal law restricts this drug to use by or on the order of a licensed veterinarian. |
| Tolerances |
Tolerances are established for residues of parent neomycin in uncooked edible tissues as follows: a. In cattle, swine, sheep, and goats: 7.2 parts per million in kidney (target tissue) and fat, 3.6 ppm in liver, and 1.2 ppm in muscle. b. In turkeys: 7.2 ppm in skin with adhering fat, 3.6 parts per million in liver, and 1.2 ppm in muscle. c. In milk: 0.15 part per million. |